Systemic Sclerosis Clinical and Biomarker Study
NCT02531009 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2015-11-02
Summary
The primary objective of the study is to assess the change in systemic sclerosis (SSc)-associated gastrointestinal (GI) tract symptoms over a 1-year period in participants with SSc.
Conditions
- Healthy
- Systemic Sclerosis
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Medical Director · Biogen
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-12-31
- Primary Completion
- 2017-03-31
- Completion
- 2017-03-31
More Related Trials
-
Evaluating Gut Imaging and Stool Biomarkers in Patients With Scleroderma-associated Gastrointestinal Disease
NCT04630782 ·Status: UNKNOWN
-
Genesis of Scleroderma: Role of Environmental Factors in 100 Patients With Scleroderma and 300 Controls
NCT00213525 ·Status: COMPLETED
-
An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)
NCT05626751 ·Status: TERMINATED ·Phase: PHASE2
-
Oral Health and People With Systemic Sclerosis
NCT01817361 ·Status: COMPLETED
-
Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis
NCT02339441 ·Status: COMPLETED
-
Stem Cell Factor, a Potential Biological Marker of Skin Involvement in Systemic Sclerosis?
NCT05482594 ·Status: UNKNOWN
-
Gut Microbiota Transplantation in Systemic Sclerosis
NCT03444220 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Implementation of a Biological Sample Collection in Systemic Sclerosis Patients
NCT04986514 ·Status: WITHDRAWN
-
Taking Charge of Systemic Sclerosis
NCT02494401 ·Status: COMPLETED ·Phase: NA
-
A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms
NCT05559580 ·Status: COMPLETED ·Phase: PHASE2
-
Prospective Cohort of Patients With Systemic Sclerosis at Brest University Hospital With Biobanking
NCT05532865 ·Status: RECRUITING
-
Periodontal Microbiota in Systemic Sclerosis
NCT06182293 ·Status: RECRUITING ·Phase: NA
-
Clinical and Paraclinical Characteristics of the Systemic Scleroderma Cohort According to the Criteria ACR 2013 and the History of Professional Exposure or of Agricultural Environment
NCT03262922 ·Status: COMPLETED
-
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
NCT02283762 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
NCT06375005 ·Status: RECRUITING ·Phase: PHASE2
-
Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis
NCT00667134 ·Status: COMPLETED
-
The Gut and Skin Microbiome in Vitiligo Disease Progression
NCT03577327 ·Status: RECRUITING
-
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
NCT02588625 ·Status: WITHDRAWN ·Phase: PHASE2
-
Analysis of Dermal Fibroblasts and Immune Cells During Systemic Sclerosis
NCT05273138 ·Status: RECRUITING
-
Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis
NCT03041025 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis
NCT04440592 ·Status: COMPLETED ·Phase: PHASE2
-
AUTOANTIBODIES AND SYSTEMIC SCLEROSIS
NCT06502678 ·Status: NOT_YET_RECRUITING
-
Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension
NCT02331225 ·Status: COMPLETED
-
Longitudinal Spatial Frequency Domain Imaging Study
NCT05672992 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Pathogenic Mechanisms Involved in the Initiation and Progression of Systemic Sclerosis
NCT07015060 ·Status: NOT_YET_RECRUITING ·Phase: NA